Pharmawire quotes Dr. Kantor on Gilenya launch

You heard it here first.

Please see the Pharmawire article below:

Novartis' new oral MS drug Gilenya official US launch date 4 October, company confirms Pharmawire

Novartis (NYSE:NVS) plans to launch its new oral multiple sclerosis (MS) drug Gilenya (formerly Gilenia) on 4 October, according to Dr Daniel Kantor, Medical Director, Neurologique Foundation in Florida. A spokesperson for Novartis confirmed that in the US, physicians will be able to prescribe Gilenya starting on 4 October 2010. Gilenya is the first oral disease-modifying therapy for the treatment of relapsing remitting multiple sclerosis (MS). The company will be hosting an upcoming internal launch meeting in Orlando, Kantor said. Novartis also plans to host a web conference with physicians to discuss this new treatment on 7 October, he noted. by Kimberly Ha

- Dr. Daniel Kantor, MD BSE

Medical Director

Neurologique

info@neurologique.org

www.neurologique.org